Published in Clin Chem on July 22, 2011
Cardiac troponin level elevations not related to acute coronary syndromes. Nat Rev Cardiol (2013) 1.71
Cardiac myosin-binding protein C: a potential early biomarker of myocardial injury. Basic Res Cardiol (2015) 1.52
High-sensitivity troponin assays: evidence, indications, and reasonable use. J Am Heart Assoc (2014) 0.88
High-sensitive cardiac troponin T. J Geriatr Cardiol (2013) 0.81
Typical rise and fall of troponin in (peri-procedural) myocardial infarction: A systematic review. World J Cardiol (2016) 0.75
High-sensitivity cardiac troponin assays--change is important. Clin Chem (2011) 0.75
A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet (2011) 5.61
N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol (2009) 4.00
2-Hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. J Am Coll Cardiol (2012) 3.15
Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol (2007) 2.60
Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation (2005) 2.34
Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. J Am Coll Cardiol (2013) 2.28
B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia. Circulation (2010) 2.26
A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. Am Heart J (2008) 2.04
Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res (2009) 1.83
Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol (2003) 1.80
Cardiac biomarkers in acute myocardial infarction. Int J Cardiol (2012) 1.71
Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J (2008) 1.58
Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol (2003) 1.55
Serial Doppler echocardiography and tissue Doppler imaging in the detection of elevated directly measured left atrial pressure in ambulant subjects with chronic heart failure. JACC Cardiovasc Imaging (2011) 1.54
Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients. Am Heart J (2006) 1.52
Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovasc Drugs Ther (2009) 1.49
ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail (2012) 1.47
Systematic review and meta-analysis of pregnant patients investigated for suspected pulmonary embolism in the emergency department. Acad Emerg Med (2014) 1.45
High-sensitivity troponin T for early rule-out of myocardial infarction in recent onset chest pain. Emerg Med J (2011) 1.44
Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device. Circulation (2007) 1.43
Biology of the natriuretic peptides. Am J Cardiol (2008) 1.41
N-terminal pro-C-type natriuretic peptide, but not C-type natriuretic peptide, is greatly elevated in the fetal circulation. Clin Sci (Lond) (2004) 1.41
Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol (2004) 1.41
Highly sensitive troponin assays--a two-edged sword? Med J Aust (2012) 1.39
Limited utility of exercise stress testing in the evaluation of suspected acute coronary syndrome in patients aged less than 40 years with intermediate risk features. Emerg Med Australas (2014) 1.39
Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation (2003) 1.38
New biomarkers in heart failure: applications in diagnosis, prognosis and guidance of therapy. Rev Esp Cardiol (2010) 1.38
Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol (2008) 1.35
Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol (2006) 1.25
A new improved accelerated diagnostic protocol safely identifies low-risk patients with chest pain in the emergency department. Acad Emerg Med (2012) 1.21
A common variant at chromosome 9P21.3 is associated with age of onset of coronary disease but not subsequent mortality. Circ Cardiovasc Genet (2010) 1.21
Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis(†): Meta-Analysis Global Group in Chronic heart failure (MAGGIC). Eur J Heart Fail (2012) 1.21
The HEART score for the assessment of patients with chest pain in the emergency department: a multinational validation study. Crit Pathw Cardiol (2013) 1.20
Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol (2003) 1.20
Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail (2013) 1.20
Genomic selection of reference genes for real-time PCR in human myocardium. BMC Med Genomics (2008) 1.19
Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol (2011) 1.17
A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J (2006) 1.11
What is an acceptable risk of major adverse cardiac event in chest pain patients soon after discharge from the Emergency Department?: a clinical survey. Int J Cardiol (2012) 1.10
Cardiac natriuretic peptides for cardiac health. Clin Sci (Lond) (2005) 1.06
Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol (2007) 1.06
Severe obstructive sleep apnea and outcomes following myocardial infarction. J Clin Sleep Med (2011) 1.06
The neuro-cardio-endocrine response to acute subarachnoid haemorrhage. Clin Endocrinol (Oxf) (2002) 1.04
Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. J Am Coll Cardiol (2013) 1.02
Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction. Endocrinology (2008) 1.01
Diagnostic and prognostic utility of early measurement with high-sensitivity troponin T assay in patients presenting with chest pain. CMAJ (2012) 1.01
B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. Am J Cardiol (2005) 0.99
Development and validation of the Emergency Department Assessment of Chest pain Score and 2 h accelerated diagnostic protocol. Emerg Med Australas (2014) 0.98
Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses. J Am Coll Cardiol (2007) 0.98
Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol (2005) 0.98
Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol (2003) 0.98
Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J (2006) 0.97
Resistin worsens cardiac ischaemia-reperfusion injury. Biochem Biophys Res Commun (2006) 0.97
Regional release and clearance of C-type natriuretic peptides in the human circulation and relation to cardiac function. Hypertension (2009) 0.97
Plasma lipids and betaine are related in an acute coronary syndrome cohort. PLoS One (2011) 0.97
Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J (2005) 0.96
Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol (2002) 0.96
Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation (2006) 0.96
Human cerebral arteriovenous vasoactive exchange during alterations in arterial blood gases. J Appl Physiol (1985) (2008) 0.96
Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med (2007) 0.94
Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol (2006) 0.93
Urocortin-1 infusion in normal humans. J Clin Endocrinol Metab (2004) 0.92
The chromosome 9p21.3 coronary heart disease risk allele is associated with altered gene expression in normal heart and vascular tissues. PLoS One (2012) 0.91
Prolonged urocortin 2 administration in experimental heart failure: sustained hemodynamic, endocrine, and renal effects. Hypertension (2011) 0.91
Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury. Clin Sci (Lond) (2008) 0.91
The effects of medications on circulating levels of cardiac natriuretic peptides. Ann Med (2007) 0.91
Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. Eur J Heart Fail (2013) 0.91
Characterisation of proghrelin peptides in mammalian tissue and plasma. J Endocrinol (2007) 0.90
Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res (2005) 0.90
Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension (2006) 0.90
Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: The POMPE-C tool. Thromb Res (2012) 0.90
Prediction of cardiac rhythm 1 year following cardioversion for atrial fibrillation. N Z Med J (2011) 0.90
Betaine and secondary events in an acute coronary syndrome cohort. PLoS One (2012) 0.90
Plasma corin levels provide minimal prognostic utility incremental to natriuretic peptides in chronic systolic heart failure. J Card Fail (2010) 0.89
NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail (2006) 0.89
Adrenomedullin expression in rat uterus is correlated with plasma estradiol. Am J Physiol Endocrinol Metab (2002) 0.89
Characteristics of aortic wall extracellular matrix in patients with acute myocardial infarction: tissue microarray detection of collagen I, collagen III and elastin levels. Interact Cardiovasc Thorac Surg (2012) 0.89
Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail (2014) 0.89
Generation and characterization of a mouse model of the metabolic syndrome: apolipoprotein E and aromatase double knockout mice. Am J Physiol Endocrinol Metab (2011) 0.89
Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failure. Hypertension (2006) 0.88
Genomic risk variants at 1p13.3, 1q41, and 3q22.3 are associated with subsequent cardiovascular outcomes in healthy controls and in established coronary artery disease. Circ Cardiovasc Genet (2011) 0.87
Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development. Biochim Biophys Acta (2009) 0.87
Comparison of infarct-derived and control ovine cardiac myofibroblasts in culture: response to cytokines and natriuretic peptide receptor expression profiles. Am J Physiol Heart Circ Physiol (2006) 0.87
Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma. Eur J Heart Fail (2009) 0.87
How useful are laboratory investigations in the emergency department evaluation of possible osteomyelitis? Emerg Med Australas (2011) 0.86
Amino-terminal proCNP: a putative marker of cartilage activity in postnatal growth. Pediatr Res (2005) 0.86
Monitoring of heart failure: comparison of left atrial pressure with intrathoracic impedance and natriuretic peptide measurements in an experimental model of ovine heart failure. Clin Sci (Lond) (2011) 0.86
Plasma urocortin 1 in human heart failure. Circ Heart Fail (2009) 0.86
Urotensin II immunoreactivity in the human circulation: evidence for widespread tissue release. Clin Chem (2009) 0.86
Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep. J Endocrinol (2006) 0.86
Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure. Hypertension (2002) 0.85
Renal and cardiac function for long-term (10 year) risk stratification after myocardial infarction. Eur Heart J (2009) 0.85
Introduction of an accelerated diagnostic protocol in the assessment of emergency department patients with possible acute coronary syndrome: the Nambour Short Low-Intermediate Chest pain project. Emerg Med Australas (2013) 0.84
B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. JACC Cardiovasc Imaging (2009) 0.84
OSA and coronary plaque characteristics. Chest (2014) 0.83
First identification of circulating prepro-A-type natriuretic peptide (preproANP) signal peptide fragments in humans: initial assessment as cardiovascular biomarkers. Clin Chem (2012) 0.83